logo
Weekly nightmares ‘triple the risk of an early death' as scientists reveal what to do NOW

Weekly nightmares ‘triple the risk of an early death' as scientists reveal what to do NOW

The Sun23-06-2025
PEOPLE who suffer from weekly nightmares could be at higher risk of early death, researchers have warned.
Adults who reported weekly nightmares were over three times more likely to die before the age of 70, compared to those who rarely or never had them, they found.
1
Researchers said night terrors were a 'stronger predictor of premature death' than other established risk factors, such as smoking, obesity, unhealthy diets and lack of exercise.
They also linked frequent nightmares to accelerated biological ageing.
Off the back of their findings, researchers shared "simple measures" to prevent nightmares - including "avoiding scary movies", setting up a good bedtime routine and keeping stress under control.
The team - led by Dr Abidemi Otaiku of the UK Dementia Research Institute, and Imperial College London - analysed data from 2,429 children aged eight to 10 and 183,012 adults aged 26 to 86 over a period of 19 years.
Adults were asked to report how often they experienced nightmares at the start of the study, while the parents of child participants reported how often their little ones suffered night terrors.
Meanwhile, participants' biological age was assessed by measuring the length of their telomeres – small DNA sequences that serve as indicators of cellular ageing.
The research, which was presented at the European Academy of Neurology (EAN) Congress this month, found that nightmares disrupt both sleep quality and duration.
This impairs the body's ability to repair itself and restore cells throughout the night.
Dr Otaiku said: 'Our sleeping brains cannot distinguish dreams from reality.
'That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered.
"This stress reaction can be even more intense than anything we experience while awake.'
The combination of chronic stress and disrupted sleep likely speed up the ageing of our cells and bodies, study authors said.
Results showed that adults who reported weekly nightmares were more than three times as likely to die prematurely - which researchers described as before the of age 70 - compared to those who rarely or never experienced nightmares.
Children and adults with more frequent nightmares also exhibited faster biological ageing, which accounted for approximately 40 per cent of their heightened risk of death.
Dr Otaiku added: 'Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing. For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process.
"Additionally, nightmares disrupt both sleep quality and duration, impairing the body's essential overnight cellular restoration and repair.
"The combined effects of chronic stress and disrupted sleep likely contribute to the accelerated ageing of our cells and bodies.'
Even monthly nightmares were linked to faster ageing and increased mortality compared to rare or no nightmares, study authors found.
Tips to combat stress
The Stress Management Society says . . .
STAY CONNECTED. Look after your social wellbeing by staying in touch with others. Pick up the phone, talk, and ask for help.
GET ENOUGH SLEEP. Set up a good bedtime routine and make your bedroom a tech-free zone. This will force you to switch off in this 'always on' world.
PRIORITISE AND ORGANISE. Even if you work from home, try to keep work and personal space separate, create boundaries and prioritise the most important tasks for the start of the day.
EAT HEALTHILY. Reduce sugar consumption to avoid energy crashes, avoid relying on stimulants such as caffeine and nicotine, and drink plenty of water to stay hydrated.
SELF-CARE. Make time for things you enjoy and leave you feeling relaxed, whether it's mindfulness, reading, a walk, sport or watching TV.
See stress.org.uk.
The link between frequent nightmares and accelerated ageing was observed across all ages, sexes, ethnicities, and mental health conditions, which researchers said indicates a universal effect.
The findings highlight the importance of reducing nightmare frequency across the population.
'The good news is that nightmares can be prevented and treated', Dr Otaiku said.
'Simple measures like avoiding scary movies, maintaining good sleep hygiene, managing stress, and seeking treatment for anxiety or depression can be effective.
'Those experiencing frequent nightmares that disrupt their quality of life may benefit from seeing a sleep specialist.
"Effective psychological treatments, such as image rehearsal therapy, can be practised at home.
"Recent research also suggests that therapies like CBT-I, which reduce nightmares, may significantly slow the ageing process', he added.
Reflecting on the broader public health significance of these findings, Dr Otaiku stated: 'Given how common and modifiable nightmares are, they should be taken far more seriously as a public health concern.
'If further studies confirm the causal impact of nightmares on ageing and brain health, then preventing and treating them could become one of the simplest, most cost-effective strategies to slow ageing at a population level.
"This would not only improve individual well-being but also help achieve the United Nations Sustainable Development Goal of reducing premature death worldwide and promoting health for all.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharmacy warning of unsustainable demand for weight loss medication
Pharmacy warning of unsustainable demand for weight loss medication

The Independent

time3 minutes ago

  • The Independent

Pharmacy warning of unsustainable demand for weight loss medication

The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

Roche to investigate whether new drug can delay or prevent Alzheimer's disease
Roche to investigate whether new drug can delay or prevent Alzheimer's disease

Reuters

time33 minutes ago

  • Reuters

Roche to investigate whether new drug can delay or prevent Alzheimer's disease

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

Reuters

time2 hours ago

  • Reuters

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store